JACOB LEONARD S 4
4 · ANTARES PHARMA, INC. · Filed Apr 10, 2019
Insider Transaction Report
Form 4
JACOB LEONARD S
Director
Transactions
- Exercise/Conversion
Common Stock
2019-04-08$0.53/sh+30,000$15,900→ 331,970 total - Exercise/Conversion
Stock Option (right to buy)
2019-04-08−30,000→ 0 totalExercise: $0.53Exp: 2019-05-14→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2019-04-08$0.53/sh+62,078$32,901→ 301,970 total - Sale
Common Stock
2019-04-08$3.00/sh−92,078$276,243→ 239,892 total - Exercise/Conversion
Stock Option (right to buy)
2019-04-08−62,078→ 0 totalExercise: $0.53Exp: 2019-05-14→ Common Stock (62,078 underlying)
Footnotes (2)
- [F1]The stock option exercises and sale of common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The stock options were due to expire on May 14, 2019.
- [F2]The options vested and became exercisable in four equal quarterly installments following the grant date of May 14, 2009.